Clinical trials: Epithelial Cancer Patients
Recurrent Glioblastoma Multiforme, Malignant Glioma
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both…
- Conditions
- Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
- Trial name
- NCT01738646
- Testing
- Vorinostat, Bevacizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Carcinoma, Non-small-cell Lung
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer.
- Trial name
- NCT00125359
- Testing
- erlotinib and bexarotene
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Konstantin Dragnev
Carcinoid Tumor, Malignant Carcinoid Syndrome
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid…
- Trial name
- RADIANT-2 (NCT00412061)
- Testing
- Octreotide, Everolimus
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 429 people
- Sponsor
- Novartis Pharmaceuticals
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
This was a Phase 1, non-randomized, open-label, multicenter study of the ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine administered with the granulocyte macrophage-colony stimulating factor (GM-CSF) sargramostim in patients with NY-ESO-1…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00803569
- Testing
- ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ludwig Institute for Cancer Research
Renal Cell Carcinoma
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg…
- Trial name
- INTORSECT (NCT00474786)
- Testing
- Sorafenib, temsirolimus (Torisel)
- Where
- 128 sites in United States, Argentina and 18 more
- Volunteers
- 512 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally…
- Trial name
- CONTACT-03 (NCT04338269)
- Testing
- Atezolizumab, Cabozantinib
- Where
- 135 sites in United States, Argentina and 13 more
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Neuroblastoma
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer. Antibodies are made by the body to attack tumors and to fight infections.
- Trial name
- NCT01183429
- Testing
- 3F8 and 13-cis-retinoic acid
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-melanomatous Skin Cancer, Precancerous Condition
Photodynamic Therapy in Treating Patients With Skin Cancer
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer.
- Trial name
- NCT00002975
- Testing
- aminolevulinic acid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma, Liver Cancer
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT01264705
- Testing
- bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Cancer, Mucositis
Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
RATIONALE: Growth factors, such as palifermin, may lessen the severity of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
- Trial name
- NCT00360971
- Testing
- palifermin, cisplatin, neck dissection
- Where
- 48 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Clear Cell Renal Cell Carcinoma
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
- Trial name
- NCT03680521
- Testing
- Sitravatinib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mirati Therapeutics Inc.
Malignant Mesothelioma
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in…
- Trial name
- NCT01085630
- Testing
- pemetrexed disodium, clinical observation
- Where
- 145 sites in United States
- Volunteers
- 72 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Renal Cell
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who…
- Trial name
- NCT00073307
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 121 sites in United States, Argentina and 17 more
- Volunteers
- 903 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Patients will be enrolled based on presence of HCC and eligibility for TACE. They will be randomized to one of two arms for imaging navigation to the optimal catheter location for chemotherapy injection to treat the first…
- Trial name
- NCT00926536
- Testing
- C-arm CT + DSA as needed, DSA only
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Stanford University
Glioma, Glioma of Brain
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
This protocol is designed to assess the need for seizure prophylaxis in the perioperative period for patients undergoing neurosurgical procedure (gross-total resection, sub-total resection or biopsy) for suspected diagnosis of…
- Conditions
- Glioma, Glioma of Brain, Brain Tumor
- Trial name
- NCT03436433
- Testing
- Lacosamide, Levetiracetam
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Renal Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
This is a Phase II, multicenter, randomized, blinded, placebo-controlled study designed to evaluate the safety and efficacy of combining bevacizumab with sunitinib relative to placebo with sunitinib in patients with metastatic…
- Trial name
- NCT00491738
- Testing
- bevacizumab, sunitinib
- Volunteers
- 16 people
- Sponsor
- Genentech, Inc.
Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body.
- Trial name
- NCT02899078
- Testing
- Ibrutinib, Nivolumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of California, Davis
Glioma
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
This study will determine whether the drugs tamoxifen and bortezomib can delay tumor growth in patients with recurrent glioma (malignant brain tumor).
- Trial name
- NCT00108069
- Testing
- Tamoxifen citrate, Bortezomib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
High-Grade Gliomas
Bevacizumab and Irinotecan to Treat Brain Tumors
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. It has shown activity against human brain tumors in laboratory tests and human clinical trials.
- Trial name
- NCT00393094
- Testing
- Bevacizumab, Irinotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate…
- Trial name
- NCT00613028
- Testing
- Temo + Avastin, VP-16 + Avastin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.